# US 2015/0177244 A1 · Parallel analysis of serum epcam and mmp7 to discriminate sepsis, necrotizing enterocolitis and normal control patients

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177244 A1
- Document ID: US20150177244A1
- Status: Published application
- Kind: A1
- Application number: 14/576,967
- Filed: 2014-12-19
- Published: 2015-06-25
- Earliest claimed: 2013-12-20
- Applicants: The Board of Trustees of the Leland Stanford Junior University
- Inventors: Bruce Xuefeng Ling; Karl G. Sylvester; Changlin Fu; Shan Xiang Wang; Dokyoon Kim
- Web page: https://patentgrep.com/patent/US20150177244A1

## CPC

- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2333/4737: C-reactive protein
- G01N 2333/70503: Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N 2333/96494: Matrix metalloproteases, e. g. 3.4.24.7
- G01N 2800/067: Pancreatitis or colitis
- G01N 2800/26: Infectious diseases, e.g. generalised sepsis
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods and compositions are provided for making a necrotizing enterocolitis (NEC) or sepsis assessment of an individual. Aspects of the methods include detecting a biomarker or panel of biomarkers selected from MMP7, EpCAM, and CRP. In addition, reagents, devices, systems and kits thereof that find use in practicing the subject methods are provided.

## Claims

### Claim 1

A method of making an NEC/sepsis assessment of a subject, the method comprising:
detecting the level of MMP7 in a blood sample from a subject to arrive at a biomarker signature representative of the level of MMP7 in the sample, and
making the NEC/sepsis assessment of a subject based upon the biomarker signature.

### Claim 2 (depends on 1)

The method according to claim 1, further comprising detecting the level of EpCAM in the blood sample to arrive at a biomarkers signature representative of the levels of MMP7 and EpCAM in the sample, and
making the NEC/sepsis assessment based upon the biomarker signature.

### Claim 3 (depends on 2)

The method according to claim 2, further comprising detecting the level of C-reactive protein (CRP) in the blood sample to arrive at a biomarkers signature representative of the levels of MMP7, EpCAM, and CRP in the sample, and
making the NEC/sepsis assessment based upon the biomarker signature.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the assessment is a diagnosis of the subject, and the subject is at risk for having NEC or sepsis.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the assessment is a monitoring of the subject, and the subject has NEC or sepsis.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the assessment is a determination of treatment, and the method comprises selecting a treatment for the subject based upon the NEC/sepsis assessment.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the detecting comprises the use of a magnetic nanoparticle sensor.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the making of the NEC/sepsis assessment comprises comparing the biomarker signature to a reference biomarker signature, and making the assessment based on the comparison.

### Claim 9 (depends on 8)

The method according to claim 8, wherein the reference biomarker signature is an NEC-positive reference biomarker signature and/or a sepsis-positive reference biomarker signature.

### Claim 10

(canceled)

### Claim 11

A device for making an NEC or sepsis assessment, the device comprising a magnetic nanoparticle sensor configured to detect one or more proteins selected from MMP7, EpCAM and CRP in a fluid sample from a subject.

### Claim 12 (depends on 11)

The device according to claim 11, wherein the magnetic nanoparticle sensor is configured to detect MMP7 and EpCAM.

### Claim 13 (depends on 11)

The device according to claim 11, wherein the magnetic nanoparticle sensor is configured to detect MMP7, EpCAM, and CRP.

### Claim 14 (depends on 11)

The device according to claim 11, wherein the fluid sample is a blood sample.

### Claim 15 (depends on 11)

The device according to claim 11, wherein the fluid sample is a plasma sample.

### Claim 16 (depends on 14)

The device according to claim 14, wherein the device is configured to detect protein in a 1-100 ul sample volume.

### Claim 17 (depends on 11)

A system for diagnosing NEC or sepsis, the system comprising a device according to claim 11 and one or more references selected from a NEC-positive reference and a sepsis-positive reference.

### Claim 18

A kit comprising:
one or more biotinylated antibodies selected from a biotinylated antibody specific for MMP7, a biotinylated antibody specific for EpCAM, and a biotinylated antibody specific for CRP; and
streptavidin-labeled magnetic nanoparticles.

### Claim 19 (depends on 11, 18)

The kit according to claim 18, further comprising:
a device according to claim 11.
